N- and K-ras oncogene mutations represent the most frequent molecular lesions in plasma cell dyscrasias. They are not randomly distributed since they are detectable in multiple myeloma (MM) (9-31%) and plasma cell leukemia (PCL) (30%), and not in monoclonal gammopathy of undetermined significance (MGUS) and solitary plasmacytoma (SP). Codons 12, 13 and 61 of N- and K-ras genes have been found mutated. Mutations affecting codon 61 of N-ras gene are the most frequent finding. A heterogeneous pattern of mutations is described with a prevalence of purine-pyrimidine transversions. Ras gene mutations have been predominantly detected in myelomas characterized by an advanced stage disease, and adverse prognostic parameters. These findings suggest that ras mutations represent a late molecular lesion and may be implicated in tumor progression rather than tumor initiation.

N- and K-ras oncogenes in plasma cell dyscrasias / P. Corradini, M. Ladetto, G. Inghirami, M. Boccadoro, A. Pileri. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 15:1-2(1994 Sep), pp. 17-20-20.

N- and K-ras oncogenes in plasma cell dyscrasias

P. Corradini;
1994-09

Abstract

N- and K-ras oncogene mutations represent the most frequent molecular lesions in plasma cell dyscrasias. They are not randomly distributed since they are detectable in multiple myeloma (MM) (9-31%) and plasma cell leukemia (PCL) (30%), and not in monoclonal gammopathy of undetermined significance (MGUS) and solitary plasmacytoma (SP). Codons 12, 13 and 61 of N- and K-ras genes have been found mutated. Mutations affecting codon 61 of N-ras gene are the most frequent finding. A heterogeneous pattern of mutations is described with a prevalence of purine-pyrimidine transversions. Ras gene mutations have been predominantly detected in myelomas characterized by an advanced stage disease, and adverse prognostic parameters. These findings suggest that ras mutations represent a late molecular lesion and may be implicated in tumor progression rather than tumor initiation.
Genes, ras; Plasmacytoma; Humans; DNA Mutational Analysis; Prognosis; Point Mutation; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Leukemia, Plasma Cell; Polymorphism, Single-Stranded Conformational; Multiple Myeloma
Settore MED/15 - Malattie del Sangue
LEUKEMIA & LYMPHOMA
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/182248
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 22
social impact